TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* PATIENT PARTICIPANTS~* Patients with newly diagnosed or recurrent gynecologic cancer (ovarian, uterine, cervical, vaginal, vulvar) actively undergoing treatment (chemotherapy, surgery, or radiation therapy) at COH (including Duarte and South Pasadena campuses)~* English-speaking patients~* PEER MENTORS~* Peer mentors will be past gynecologic cancer patients not currently undergoing treatment for their cancer, and considered without evidence of disease~* Over age 18~* PEER MENTORS: English-speaking patients~* This study is open to patients of all races and ethnicities~Exclusion Criteria:~* PEER MENTORS:~* Major psychiatric disease~* Currently undergoing treatment for active gynecologic cancer

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Supportive care (W2W program) (Type: EXPERIMENTAL): Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologic confirmation of malignant pleural mesothelioma~* Patients who are able to tolerate surgical cytoreduction but unable to undergo extrapleural pneumonectomy due to poor cardiopulmonary reserve or tumor invasion or those with minimal disease~* Male on non-pregnant female~* 18 years of age or older~* No evidence of spread outside the ipsilateral hemithorax by chest CT and chest MRI~* Ejection fraction \> 45%~* Pre-operative WBC \> 4K/uL~* Estimated life expectancy of at least 12 weeks~* Evidence of adequate renal and hepatic function~* Grossly normal contralateral pulmonary function with a chest radiograph and chest CT scan~* Karnofsky performance status of 70% or greater~* No evidence of disease progression by chest CT or chest MRI, obtained at 8 weeks following surgery~Exclusion Criteria:~* Extended disease outside the ipsilateral hemithorax as determined on pre-operative radiographs or intraoperative findings~* Positive extrapleural nodes as determined by mediastinoscopy~* Gross disease (estimated thickness \> 10mm at any intrathoracic location) present within the hemithorax after surgery~* Evidence of distant metastatic disease~* Severe non-malignant co-morbid disease, uncontrolled angina, myocardial infarction on the past 6 months, renal insufficiency, liver disease, pulmonary hypertension~* Pregnant or breast-feeding~* Serious concomitant systemic disorders~* Presence of active concomitant malignancy~* Psychiatric or addictive disorders, which would preclude informed consent~* Previous chemotherapy or radiation therapy for mesothelioma~* Chemotherapy or radiation therapy administered within 3 years for another malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Surgery+Heated Cisplatin+Sodium Thiosulfate+Adjuvant CT (Type: EXPERIMENTAL): Participants undergo surgery, Pleurectomy/Decortication, followed by heated cisplatin given as a one-hour lavage of the chest and abdominal cavity then sodium thiosulfate given intravenously over 6 hours. The adjuvant chemotherapy regimen beginning 6-10 weeks after surgery is a combination of cisplatin and Alimta each given day 1 of a 21-day cycle for 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comprehensive Analysis of Respiratory Events Using Smartphone Systems

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* referred for polysomnography (PSG) because of possible obstructive sleep apnea (OSA)~* owns/possesses a smartphone for use during the study. Must be:~  * Android models running Android OS Samsung Galaxy 5 or later~ * iPhone models running iOS 6 or later~Exclusion Criteria:~* previous PSG or home sleep testing (HST) confirmation of OSA~* prior surgery for snoring or OSA~* medical contraindication of HST, as applicable~* congnitive impairment that might interfere with obtaining informed consent, or completing Clinical Questionnaire

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Moderate to severe abdominal pain due to chronic pancreatitis of at least 6 months duration.~Exclusion criteria:~* Mild pain on the Pain Intensity-Numeric Rating Scale \[PI-NRS\] at screening and randomization visits;~* Narcotic addiction;~* Recent pancreatic surgical or endoscopic intervention for chronic pancreatitis pain;~* Unwillingness to use study-defined rescue analgesia exclusively.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- REGN475/SAR164877 (Type: EXPERIMENTAL): REGN475/SAR164877, single injection, dose depending on the participant's body weight
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (for REGN475/SAR164877), single injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: New Biomarkers for Invasive Fungal Infections in Paediatric Haemato-oncology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Any febrile episode in :~   * either a neutropenic child suffering from acute lymphoblastic leukemia under induction chemotherapy or relapse, acute myeloblastic leukemia under chemotherapy (all cycles of chemotherapy included) or myelodysplasic syndrome~  * an allogenetic hematopoietic stem cell transplantation recipient child, from conditioning till 3 months or receiving aggressive immunosuppressive therapy for at least 1 months~2. Age of children will be from 3 months till 18 years~3. Informed consent from the parents and from children older than 12 years obtained~Exclusion Criteria:~1. Any previous history of fungal infection (proven, probable or possible) with prescription of secondary oral prophylaxis (voriconazole or posaconazole) under current use at the time of the study.~2. Any previous episode already enrolled (only one episode/patient).

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: OTHER): single cohort of patient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Kidney Injury After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has signed and dated the EC approved informed consent~* Subject is ≥ 18 years of age~* Requires elective or urgent (non-emergency) cardiac procedure requiring the use of ECC.~* Preoperative Acute kidney injury risk score ≥30%, found at http://cardiacsurgeryleicester.com/our-research/acute-kidney-injury-risk-score-calculator/~Exclusion Criteria:~* Unable to give informed consent~* Known bleeding disorder~* Known intolerance or contraindication to dextran~* Acute Surgery (requires emergency cardiac procedure/surgery)~* Currently using an antithrombotic medication which has not been discontinued per institution protocol~* Malignancy; Surgery within 5 years or ongoing antitumoral treatment~* Has ongoing sepsis or endocarditis~* Requires pre-operative dialysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colloid priming solution for ECC circuit (Type: EXPERIMENTAL): Priming of ECC circuit with approximately 1200 mL PrimECC.
- Standard priming solution for ECC circuit (Type: ACTIVE_COMPARATOR): Priming of ECC circuit with approximately 1200 mL standard priming solution (crystalloid solution with or without mannitol addition as per routine of the participating clinic).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Levels In Patients Who Has Normal to Grade 2 Knee Arthroscopy Changes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male \& no pregnant female age between 18-40 yrs, who continue to experience knee pain following normal to Grade 2 knee arthroscopy findings.~Exclusion Criteria:~* Any types of anatomical or neurological causes for the pain, history of seizures, regional pain syndrome, alcohol or drug abuse, and malignancy, patients with clinically significant diseases and patients who do not understand English will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Knee pain patients with minimal knee changes (Type: None): Male \& no pregnant female age between 18-40 yrs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Healthy Michigan Plan Section 1115 Community Engagement Requirement Waiver

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: Enrollees eligible for the HMP community engagement requirement, including:~* Adult HMP beneficiaries ages 19-62 who are not otherwise exempt.~Exclusion Criteria: Enrollees exempt from the community engagement requirement includiung:~* Pregnant women~* Primary caregivers of a family member under six years of age (limited to one caregiver per household)~* Caretakers of a dependent with a disability who needs full-time care (allowed for one beneficiary per household if there is only one dependent with a disability who meets the criteria specified above in the household)~* Caretakers of an incapacitated individual even if the incapacitated individual is not a dependent of the caretaker~* Beneficiaries considered medically frail~* Beneficiaries currently receiving temporary or permanent long-term disability benefits from a private insurer or from the government~* Beneficiaries diagnosed with an acute medical condition that would prevent them from complying with the requirements~* Beneficiaries who have been incarcerated within the last six months~* Beneficiaries currently receiving unemployment benefits from the state~* Beneficiaries under 21 years of age who had previously been in foster care placement in Michigan~* Full-time students.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 62 Years
- Healthy Volunteers: f

Study Arms:
- Exempt for Evaluation Purposes (Type: None): Individuals who would have been subject to the Healthy Michigan Plan (HMP) work requirements but have been randomly assigned to a control group that is exempt from reporting for evaluation purposes
- Work Requirement (Type: None): Individuals who are subject to the Healthy Michigan Plan (HMP) work requirements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Patients with histologically proven (N)SCLC (all histological subtypes), treated with concurrent chemo- and radiotherapy.~* Ability to understand the protocol and willing to provide written informed consent~Exclusion Criteria:~* Concurrent participation in a clinical trial in which the subject is taking or receiving any investigational agent that may affect the frequency, severity or duration of mucositis.~* Pre-existent esophagitis.~* Receiving investigational treatment for the prevention or treatment of mucositis.~* Prior irradiation to the lung or head and neck region.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caphosol (Type: ACTIVE_COMPARATOR): None
- No intervention (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults (18 years or older) with:~  * choroidal nevus greater than or equal to 3.0 mm in longest basal diameter, or greater than or equal to 1.25 mm in apical height or:~ * choroidal melanoma located in the posterior pole (4mm or less from the center of fovea or the border of the optic nerve head)~Exclusion Criteria:~* Ocular media opacity in the tumor eye that prevents adequate functional testing or imaging and prior or concurrent retinal or choroidal disease in the tumor eye that prevents adequate functional testing or imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fatty Liver Study in Patients With Type II Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has provided informed consent in a manner approved by the Institutional Review Board (IRB) and is willing and able to comply with the trial procedures.~2. Adults at least 18 years of age at the time of consent.~3. Have type 2 diabetes mellitus.~4. Be on a stable medication with metformin (2000 mg/day) for at least 3 months prior to study enrollment.~5. Have blood A1c \>7.6% and \< 8.5% within 3 months prior to study enrollment.~6. Have fatty liver, which is diagnosed by ultrasonographic findings of bright liver within 1 year of study enrollment.~7. Stable medication for lipid lowering, blood pressure control, dietary supplements, including vitamins, for at least 3 months.~8. Women of Childbearing Potential must be willing and able to use acceptable forms of birth control while on the study.~Exclusion Criteria:~1. Currently taking medication that can affect glucose metabolism other than Metformin.~2. History of Kidney diseases that, in the opinion of the investigator , would place the subject at increased risk of participation or plasma levels of creatinine \> 1.4 for women and \> 1.5 for men.~3. History of Cirrhosis of liver, hepatitis, or other liver diseases that, in the opinion of the investigator, would place the subject at increased risk of participation.~4. Current alcohol consumption more than12 to 15 g of alcohol a day, or \>12 oz of beer, 5 oz of wine, or 1.5 oz of distilled spirits.~5. History of heart failure.~6. Concurrent participation on another research study~7. Use of an investigational agent in the 30 days prior to signing informed consent.~8. History of prior non-compliance or the presence or history of psychiatric conditions (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigators instructions.~9. Females who are pregnant or lactating~10. Current Diagnosis or History of Bladder Cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thiazolidinedione (Type: ACTIVE_COMPARATOR): (Pioglitazone, 15 mg/day)
- Lantus Insulin (Type: ACTIVE_COMPARATOR): 0.35 U per kg body weight once daily
- DPP4 inhibitor (Type: ACTIVE_COMPARATOR): Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Outcome Following Carbon Monoxide Poisoning in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 6 through 16.~2. Acute carbon monoxide poisoning. Since we will be identifying potentially eligible patients using an electronic tool, the diagnosis of CO poisoning should be established by the evaluating physician. However, with the initial contact with the patients' parents, we will confirm the diagnosis, and only those patients with CO poisoning will be eligible.~3. Willing to come to Salt Lake City or Provo for evaluation~Exclusion Criteria:~1. Prior history of neurological injury with permanent sequelae.~2. Prior history of chronic neurological disorder such as attention deficit disorder, learning disability, multiple sclerosis, cerebral palsy, demyelinating disease, meningitis with sequelae~3. Insulin dependent diabetes (due to the confound of possible brain microvascular disease and episodes of hypoglycemia)~4. Use of illicit drugs~5. Use of alcohol in excess~6. Pregnancy~7. Carbon monoxide poisoning from a suicide attempt or concomitant smoke inhalation~8. Subject or parent/guardian non-English-speaking

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- CO poisoned children (Type: None): Children, ages 6-16, who have been poisoned by carbon monoxide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effectiveness of Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women under 42 years of age~* Presence of at least 3 embryos suitable to freeze on day 2 or 3 following fertilisation based on the centre's criteria~* Written informed consent~Exclusion Criteria:~* Women using donor eggs/donor sperm~* Women undergoing preimplantation genetic diagnosis~* Women with abnormal uterine cavity shown on hysterosalpingogram or saline infusion sonogram~* Women with hydrosalpinges shown on scanning and not corrected treated~* Women with excessive ovarian response at risk of ovarian hyperstimulation where elective freeze is already planned~* Women with serum progesterone level on day of human chorionic gonadotrophin\>1.5ng/ml or 5 nmol/L~* Women whose embryos have not survived freeze-thawing in the past~* Fresh transfer is planned e.g. patients with endometriosis or adenomyosis who have received prolonged downregulation~* Only frozen transfer is planned e.g. patients receiving ovarian stimulation regimens which may have adverse impacts on the endometrium

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Control arm (Type: ACTIVE_COMPARATOR): Women allocated to the control arm will either undergo fresh embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
- Intervention arm (Type: ACTIVE_COMPARATOR): Fresh embryo transfer will not be undertaken in this group. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues